JAVIER ABEL MENÉNDEZ MENÉNDEZ

Metabolisme i Càncer
Firma
JAVIER ABEL MENÉNDEZ-MENÉNDEZ
Posició
Investigador/a Principal

Projectes

Codi oficial: Pfizer 2019 Joaquim Bosch Data inici: 05/07/2019 Data fi: 30/06/2021 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: PFIZER, S.L.U. Ajuda: 97,750 €
Codi oficial: PID2019-104055GB-I00 Data inici: 01/06/2020 Data fi: 31/05/2023 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD Ajuda: 242,000 €
Codi oficial: CP20/00003 Data inici: 01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 202,500 €

Publicacions

Cabré N, Luciano-Mateo F, Baiges-Gayà G, Fernández-Arroyo S, Rodríguez-Tomàs E, Hernández-Aguilera A, París M, Sabench F, Del Castillo D, López-Miranda J, Menéndez JA, Camps J, Joven J

Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis.

ALIMENT PHARM THERAP, 2020, 51, 374-387 dx.doi.org/10.1111/apt.15606

Hernández-Aguilera A, Fibla M, Cabré N, Luciano-Mateo F, Camps J, Fernández-Arroyo S, Martín-Paredero V, Menendez JA, Sirvent JJ, Joven J

Chemokine (C-C motif) ligand 2 and coronary artery disease: Tissue expression of functional and atypical receptors.

Cytokine, 2020, 126, 154923-154923 dx.doi.org/10.1016/j.cyto.2019.154923

Cuyàs E, Verdura S, Martin-Castillo B, Alarcón T, Lupu R, Bosch-Barrera J, Menendez JA

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy.

Cancers, 2020, 12 dx.doi.org/10.3390/cancers12071757

Cuyàs E, Gumuzio J, Verdura S, Brunet J, Bosch-Barrera J, Martin-Castillo B, Alarcón T, Encinar JA, Martin ÁG, Menendez JA

The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes.

Aging-Us, 2020, 12, 4794-4814 dx.doi.org/10.18632/aging.102887

Verdura S, Cuyàs E, Cortada E, Brunet J, Lopez-Bonet E, Martin-Castillo B, Bosch-Barrera J, Encinar JA, Menendez JA

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.

Aging-Us, 2020, 12, 8-34 dx.doi.org/10.18632/aging.102646

Bosch-Barrera J, Martin-Castillo B, Buxó M, Brunet J, Encinar JA, Menendez JA

Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.

Journal of Clinical Medicine, 2020, 9 dx.doi.org/10.3390/jcm9061770

Luciano-Mateo F, Cabré N, Fernández-Arroyo S, Baiges-Gaya G, Hernández-Aguilera A, Rodríguez-Tomàs E, Muñoz-Pinedo C, Menéndez JA, Camps J, Joven J

Chemokine C-C motif ligand 2 overexpression drives tissue-specific metabolic responses in the liver and muscle of mice.

SCIENTIFIC REPORTS, 2020, 10, 11954-11954 dx.doi.org/10.1038/s41598-020-68769-7

Menendez JA

Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.

Aging-Us, 2020, 12, 8760-8765 dx.doi.org/10.18632/aging.103347

Menendez JA

Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity.

Biomolecules, 2020, 10 dx.doi.org/10.3390/biom10050780

Encinar JA, Menendez JA

Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.

Viruses-Basel, 2020, 12 dx.doi.org/10.3390/v12050525

Formulari de contacte

menu